Patients Coming Off Anti-Obesity Medications Regain Pounds Far More Rapidly Than Those on Conventional Diets

Fresh analysis indicates that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who end traditional lifestyle plans.

Research printed in a prominent health publication points out that while overweight individuals frequently drop substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such treatments should be cognizant of the potential of quick rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.

This pace of recovery means a return to original weight in about a year and a half.

Weighing Therapies

The study, which reviewed dozens of trials involving thousands of participants, compared the outcomes of the injectable medications with older methods.

The team emphasize that individuals who shed pounds through lifestyle changes alone typically experience a less rapid creep back—approximately 0.1 kg a month—post-intervention.

Explaining the Quick Rebound

Doctors suggest the mode of action of the injections accounts for the heightened regain.

The injections imitate a body's own chemical called GLP-1, which helps regulate hunger.

"Long-term administration of the hormone levels several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Stopping of this medication means hunger is no longer kept in check, making binge eating a significant risk."

A Lifelong Issue?

Medical guidelines suggest the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.

A number of clinicians contend that, due to the high risk of weight regain, the treatment should be considered life-long.

This perspective is echoed by drug manufacturers, who say that the results "emphasize the long-term character of obesity," comparing it to managing conditions like hypertension.

Patient Accounts

Individuals who have discontinued the medication describe a sudden return of appetite.

"It was like a trigger activating and I was suddenly ravenous," recalled an individual.

The struggle is exacerbated if patients have not adopted permanent lifestyle or habit changes during therapy.

Significant Use

Recent estimates indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.

• Adoption is more common among females compared to men.
• The 40s and 50s demographic shows the greatest usage rates.
• Many access the drugs through private prescriptions rather than public health services.

In conclusion, experts stress that while these medications are powerful agents for weight loss, they are not a permanent cure and long-term success hinges on integrated lifestyle management.